Data / Public companies / SIC 8731: Commercial physical and biological research / Bioaffinity Technologies, Inc.
Bioaffinity Technologies, Inc.: revenue, net income and total assets from its latest annual report
Bioaffinity Technologies, Inc. reported revenue of $6.2 million, a net loss of $14.9 million and total assets of $11.0 million for the fiscal year ended December 31, 2025, in its annual report (10-K) filed with the SEC on March 16, 2026. It ranks 11th by revenue of 15 companies in SIC 8731, commercial physical and biological research.
SpecStream is the live web data engine for teams and agents. It reads the annual reports that companies file with the SEC, and this page is that reading. Ask for the companies of an industry, state or city with their website, number of employees and funding added from the web, and each new annual report arrives in your sheet, CRM, Slack or agent as the SEC posts it.
- SEC central index key (CIK)
- 1712762
- Industry
- SIC 8731, Commercial physical and biological research
- Business address (city and state)
- San Antonio, Texas
- Incorporated in
- Delaware
- Filer category
- Non-accelerated filer
- Fiscal year ends
- December 31
- Latest annual report
- 10-K filed March 16, 2026
- Annual and quarterly reports in the data
- 1 annual, 4 quarterly
Financials for the fiscal year ended December 31, 2025
As filed, in US dollars. The prior year value is the comparison column in the same report.
| Item | This year | Prior year | Change | Source |
|---|---|---|---|---|
| Revenue | $6,161,959 | $9,362,022 | -34.2% | sec.gov |
| Operating income | $-10,572,508 | Not listed | Not listed | sec.gov |
| Net income | $-14,909,754 | $-9,039,831 | -64.9% | sec.gov |
| Total assets | $10,960,772 | $6,513,667 | 68.3% | sec.gov |
| Total liabilities | $3,683,116 | Not listed | Not listed | sec.gov |
| Stockholders' equity | $7,277,656 | Not listed | Not listed | sec.gov |
| Cash and cash equivalents | $6,449,782 | Not listed | Not listed | sec.gov |
How it compares
- Net margin (net income over revenue)
- -242.0%
- Revenue change on the prior year
- -34.2%
- Revenue rank in SIC 8731
- 11th of 15
- Revenue rank in Texas
- 357th of 408
- Revenue rank among all companies in the data
- 3,780th of 4,486
Companies next to it by revenue in SIC 8731
Commercial physical and biological research, from the same data.
| Company | Business address | Revenue | Net income | Total assets | Revenue change |
|---|---|---|---|---|---|
| National Research Corp | Lincoln, NE | $137.4 million | $11.6 million | $134.9 million | -4% |
| Maxcyte, Inc. | Rockville, MD | $33 million | $-44,630,000 | $202.5 million | -14.5% |
| Omniab, Inc. | Emeryville, CA | $18.7 million | $-64,779,000 | $300.9 million | -29.3% |
| Foxo Technologies Inc. | West Palm Beach, FL | $16.4 million | $-12,430,390 | $44.6 million | 304% |
| Absci Corp | Vancouver, WA | $2.8 million | $-115,183,000 | $216.3 million | -38.2% |
| Ispecimen Inc. | Woburn, MA | $1.9 million | $-10,487,532 | $9.5 million | -79.2% |
| Onemednet Corp | Surrey, United Kingdom | $1.4 million | $-2,801,000 | $2.2 million | 111.4% |
| Cannabis Bioscience International Holdings, Inc. | Houston, TX | $303,022 | $-548,820 | $31,880 | 21.8% |
Updated March 16, 2026. Read from SEC Financial Statement Data Sets, filing 0001493152-26-010143. Public data from the US Securities and Exchange Commission. Companies are the registrants whose latest annual report (form 10-K, 20-F or 40-F) is in the SEC Financial Statement Data Sets for 2025 Q3 to 2026 Q3, filed through September 30, 2026. Figures are for the whole fiscal year of that report, in US dollars, as the company filed them in XBRL: SpecStream does not adjust them. The SEC does not guarantee the data sets, and they do not replace the filings. Revenue is the revenue tag the company used; banks and funds often use none. Combined totals add each company once and can include a parent and its subsidiary that both file. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.